vs
BALCHEM CORP（BCPC）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是BALCHEM CORP的2.0倍（$540.7M vs $270.7M），BALCHEM CORP净利率更高（14.9% vs -2.9%，领先17.8%），BALCHEM CORP同比增速更快（8.1% vs -14.1%），ICU MEDICAL INC自由现金流更多（$36.0M vs $33.8M），过去两年BALCHEM CORP的营收复合增速更高（7.5% vs -2.3%）
Balchem Corp是一家全球特种化学品与营养原料供应商，核心业务覆盖人类营养、动物保健、制药、工业应用四大领域，为北美、欧洲、亚太等地区的客户提供定制化专用原料产品。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
BCPC vs ICUI — 直观对比
营收规模更大
ICUI
是对方的2.0倍
$270.7M
营收增速更快
BCPC
高出22.2%
-14.1%
净利率更高
BCPC
高出17.8%
-2.9%
自由现金流更多
ICUI
多$2.1M
$33.8M
两年增速更快
BCPC
近两年复合增速
-2.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $270.7M | $540.7M |
| 净利润 | $40.3M | $-15.7M |
| 毛利率 | — | 37.5% |
| 营业利润率 | 20.5% | 1.0% |
| 净利率 | 14.9% | -2.9% |
| 营收同比 | 8.1% | -14.1% |
| 净利润同比 | 8.7% | 34.0% |
| 每股收益（稀释后） | $1.25 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCPCICUI
| Q1 26 | $270.7M | — | ||
| Q4 25 | $263.6M | $540.7M | ||
| Q3 25 | $267.6M | $537.0M | ||
| Q2 25 | $255.5M | $548.9M | ||
| Q1 25 | $250.5M | $604.7M | ||
| Q4 24 | $240.0M | $629.8M | ||
| Q3 24 | $239.9M | $589.1M | ||
| Q2 24 | $234.1M | $596.5M |
净利润BCPCICUI
| Q1 26 | $40.3M | — | ||
| Q4 25 | $39.2M | $-15.7M | ||
| Q3 25 | $40.3M | $-3.4M | ||
| Q2 25 | $38.3M | $35.3M | ||
| Q1 25 | $37.1M | $-15.5M | ||
| Q4 24 | $33.6M | $-23.8M | ||
| Q3 24 | $33.8M | $-33.0M | ||
| Q2 24 | $32.1M | $-21.4M |
毛利率BCPCICUI
| Q1 26 | — | — | ||
| Q4 25 | 35.6% | 37.5% | ||
| Q3 25 | 35.7% | 37.4% | ||
| Q2 25 | 36.4% | 37.9% | ||
| Q1 25 | 35.2% | 34.7% | ||
| Q4 24 | 36.0% | 36.1% | ||
| Q3 24 | 35.6% | 34.8% | ||
| Q2 24 | 35.5% | 34.8% |
营业利润率BCPCICUI
| Q1 26 | 20.5% | — | ||
| Q4 25 | 19.8% | 1.0% | ||
| Q3 25 | 20.4% | 2.6% | ||
| Q2 25 | 20.1% | 1.9% | ||
| Q1 25 | 20.4% | 2.1% | ||
| Q4 24 | 19.8% | 6.0% | ||
| Q3 24 | 20.0% | 1.4% | ||
| Q2 24 | 19.6% | 1.3% |
净利率BCPCICUI
| Q1 26 | 14.9% | — | ||
| Q4 25 | 14.9% | -2.9% | ||
| Q3 25 | 15.1% | -0.6% | ||
| Q2 25 | 15.0% | 6.4% | ||
| Q1 25 | 14.8% | -2.6% | ||
| Q4 24 | 14.0% | -3.8% | ||
| Q3 24 | 14.1% | -5.6% | ||
| Q2 24 | 13.7% | -3.6% |
每股收益（稀释后）BCPCICUI
| Q1 26 | $1.25 | — | ||
| Q4 25 | $1.21 | $-0.63 | ||
| Q3 25 | $1.24 | $-0.14 | ||
| Q2 25 | $1.17 | $1.43 | ||
| Q1 25 | $1.13 | $-0.63 | ||
| Q4 24 | $1.03 | $-0.97 | ||
| Q3 24 | $1.03 | $-1.35 | ||
| Q2 24 | $0.98 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $72.9M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.3B | $2.1B |
| 总资产 | $1.7B | $4.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCPCICUI
| Q1 26 | $72.9M | — | ||
| Q4 25 | $74.6M | — | ||
| Q3 25 | $65.1M | — | ||
| Q2 25 | $65.4M | — | ||
| Q1 25 | $49.9M | — | ||
| Q4 24 | $49.5M | $308.6M | ||
| Q3 24 | $73.7M | $312.5M | ||
| Q2 24 | $63.7M | $302.6M |
股东权益BCPCICUI
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $2.1B | ||
| Q3 25 | $1.3B | $2.1B | ||
| Q2 25 | $1.3B | $2.1B | ||
| Q1 25 | $1.2B | $2.0B | ||
| Q4 24 | $1.1B | $2.0B | ||
| Q3 24 | $1.2B | $2.0B | ||
| Q2 24 | $1.1B | $2.0B |
总资产BCPCICUI
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.7B | $4.1B | ||
| Q3 25 | $1.7B | $4.1B | ||
| Q2 25 | $1.7B | $4.1B | ||
| Q1 25 | $1.6B | $4.2B | ||
| Q4 24 | $1.6B | $4.2B | ||
| Q3 24 | $1.6B | $4.3B | ||
| Q2 24 | $1.6B | $4.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $40.1M | $60.6M |
| 自由现金流经营现金流 - 资本支出 | $33.8M | $36.0M |
| 自由现金流率自由现金流/营收 | 12.5% | 6.6% |
| 资本支出强度资本支出/营收 | 2.3% | 4.6% |
| 现金转化率经营现金流/净利润 | 0.99× | — |
| 过去12个月自由现金流最近4个季度 | — | $91.8M |
8季度趋势，按日历期对齐
经营现金流BCPCICUI
| Q1 26 | $40.1M | — | ||
| Q4 25 | $67.3M | $60.6M | ||
| Q3 25 | $65.6M | $56.7M | ||
| Q2 25 | $47.3M | $11.2M | ||
| Q1 25 | $36.5M | $51.3M | ||
| Q4 24 | $52.3M | $40.2M | ||
| Q3 24 | $51.3M | $36.1M | ||
| Q2 24 | $45.0M | $82.0M |
自由现金流BCPCICUI
| Q1 26 | $33.8M | — | ||
| Q4 25 | — | $36.0M | ||
| Q3 25 | — | $27.6M | ||
| Q2 25 | — | $-8.5M | ||
| Q1 25 | — | $36.7M | ||
| Q4 24 | — | $16.1M | ||
| Q3 24 | — | $16.2M | ||
| Q2 24 | — | $62.5M |
自由现金流率BCPCICUI
| Q1 26 | 12.5% | — | ||
| Q4 25 | — | 6.6% | ||
| Q3 25 | — | 5.1% | ||
| Q2 25 | — | -1.5% | ||
| Q1 25 | — | 6.1% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 10.5% |
资本支出强度BCPCICUI
| Q1 26 | 2.3% | — | ||
| Q4 25 | — | 4.6% | ||
| Q3 25 | — | 5.4% | ||
| Q2 25 | — | 3.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | — | 3.4% | ||
| Q2 24 | — | 3.3% |
现金转化率BCPCICUI
| Q1 26 | 0.99× | — | ||
| Q4 25 | 1.72× | — | ||
| Q3 25 | 1.63× | — | ||
| Q2 25 | 1.23× | 0.32× | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 1.40× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCPC
暂无分部数据
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
